Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Endo Licenses BioDelivery's Pain Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News

Endo Licenses BioDelivery’s Pain Drug

BEMA Buprenorphine broadens Endo's pain portfolio

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Endo Pharmaceuticals has signed a worldwide license and development agreement with U.S.-based BioDelivery Sciences International for BEMA Buprenorphine, a transmucosal form of buprenorphine that incorporates a bioerodible mucoadhesive (BEMA) technology. The drug is currently in Phase III trials for the treatment of moderate to severe chronic pain.

BioDelivery Sciences will receive an upfront payment of $30 million, royalties on sales, and as much as $150 million in milestones based on the achievement of certain clinical and regulatory milestones and certain sales targets.

“Endo is committed to serving as an integrated solutions provider for the development and commercialization of products focused on the management of pain,” said Dave Holveck, president and chief executive officer of Endo Pharmaceuticals. “The addition of BEMA Buprenorphine will broaden Endo’s portfolio of pain therapeutics, allowing us to offer an integrated suite of products that currently include Opana ER, Voltaren Gel and Lidoderm, as well as a broad range of generic pain products. We look forward to working closely with BDSI on the development of this important asset.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters